All > Waldenstrom Macroglobulinemia > Knoxville

Iopofosine I 131 multiple dose for Small Lymphocytic Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Small Lymphocytic Lymphoma+8 MoreIopofosine I 131 multiple dose - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the effectiveness of iopofosine I 131 in treating patients with various types of B-cell malignancies.

Eligible Conditions
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Marginal Zone Lymphoma
  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Central Nervous System Lymphoma
  • Waldenstrom Macroglobulinemia
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
1
19(T2)28z1xx CAR T cells
1
Odronextamab multiple dose levels

Study Objectives

2 Primary · 9 Secondary · Reporting Duration: 3 years

12 months
Part B [CLOVER-WaM] Major Response Rate
135 days
Part A [CLOVER-1] Duration of Response
Part A [CLOVER-1] Overall Response Rate
Part A [CLOVER-1] Overall Survival
Part A [CLOVER-1] Progression Free Survival
Part B [CLOVER-WaM] Clinical Benefit Rate
Part B [CLOVER-WaM] Duration of Response
Part B [CLOVER-WaM] Overall Response Rate
Part B [CLOVER-WaM] Treatment Free Survival
3 years
Part A [CLOVER-1] Time to Next Treatment
84 days
Part A [CLOVER-1] Clinical benefit rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
1
19(T2)28z1xx CAR T cells
1
Odronextamab multiple dose levels

Trial Design

8 Treatment Groups

CLR 131, intravenous administration CNS Lymphoma
1 of 8
CLR 131, intravenous administration WM
1 of 8
Iopofosine I 131, intravenous administration WM
1 of 8
Iopofosine I 131, intravenous administration CNS Lymphoma
1 of 8
CLR 131 intravenous administration NHL [CLOSED]
1 of 8
Iopofosine I 131, intravenous administration MM
1 of 8
Iopofosine I 131 intravenous administration NHL [CLOSED]
1 of 8
CLR 131, intravenous administration MM
1 of 8

Experimental Treatment

120 Total Participants · 8 Treatment Groups

Primary Treatment: Iopofosine I 131 multiple dose · No Placebo Group · Phase 2

CLR 131, intravenous administration CNS Lymphoma
Drug
Experimental Group · 1 Intervention: CLR 131 fractionated dose · Intervention Types: Drug
CLR 131, intravenous administration WMExperimental Group · 3 Interventions: CLR 131 single dose, CLR 131 multiple dose, CLR 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131, intravenous administration WMExperimental Group · 3 Interventions: Iopofosine I 131 multiple dose, Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131, intravenous administration CNS Lymphoma
Drug
Experimental Group · 1 Intervention: Iopofosine I 131 fractionated dose · Intervention Types: Drug
CLR 131 intravenous administration NHL [CLOSED]Experimental Group · 3 Interventions: CLR 131 single dose, CLR 131 multiple dose, CLR 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131, intravenous administration MMExperimental Group · 3 Interventions: Iopofosine I 131 multiple dose, Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131 intravenous administration NHL [CLOSED]Experimental Group · 3 Interventions: Iopofosine I 131 multiple dose, Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose · Intervention Types: Drug, Drug, Drug
CLR 131, intravenous administration MMExperimental Group · 3 Interventions: CLR 131 single dose, CLR 131 multiple dose, CLR 131 fractionated dose · Intervention Types: Drug, Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Cellectar Biosciences, Inc.Lead Sponsor
14 Previous Clinical Trials
1,145 Total Patients Enrolled
John Friend, MDStudy DirectorCellectar Biosciences
1 Previous Clinical Trials
30 Total Patients Enrolled
Jarrod LongcorStudy DirectorCellectar Biosciences
2 Previous Clinical Trials
80 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an estimated glomerular filtration rate of 30 mL/min/1.73 m2 or greater.
Hemoglobin ≥ 9 g/dL (last transfusion, if any, must be at least 1 week prior to study registration, and no transfusions are allowed between registration and dosing).
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top